JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, to collaboratively advance research and development in the fields of novel drugs and devices, as well as high-quality biomedicine industry development. The collaboration aims to enhance the innovation capabilities within the biopharmaceutical sector, though financial specifics of the agreement were not disclosed.
This partnership builds upon an existing relationship between the two entities. Hengrui Medicine has previously demonstrated its commitment to the region by establishing a wholly owned subsidiary, Shandong Suncadia Medicine Co., Ltd, and investing in a Category 1 drug translation center project in the Jinan Innovation Zone. These initiatives reflect Hengrui’s strategic focus on fostering a robust biopharmaceutical ecosystem and contributing to the high-quality development of the industry.
The collaboration is expected to leverage Hengrui’s expertise in pharmaceutical innovation and the Jinan Innovation Zone’s resources to drive forward novel drug manufacturing and biomedicine industry growth. This alliance underscores the importance of public-private partnerships in catalyzing advancements in medical research and development, and positions both parties to play a pivotal role in shaping the future of biopharmaceuticals.- Flcube.com
